2.要約四半期連結財務諸表及び主な注記
(1)要約四半期連結財政状態計算書
| | | | | (単位:百万円) |
| | | 前連結会計年度末 (2024年3月31日) | | 当第1四半期連結会計期間 (2024年6月30日) |
資産 | | | | | |
流動資産 | | | | | |
現金及び現金同等物 | | | 58,094 | | 54,472 |
営業債権及びその他の債権 | | | 47,237 | | 48,357 |
棚卸資産 | | | 39,111 | | 37,428 |
その他の金融資産 | | | 10,609 | | 10,630 |
その他の流動資産 | | | 9,232 | | 9,084 |
流動資産合計 | | | 164,285 | | 159,973 |
非流動資産 | | | | | |
有形固定資産 | | | 33,582 | | 34,324 |
無形資産 | | | 25,120 | | 29,436 |
使用権資産 | | | 2,971 | | 2,701 |
その他の金融資産 | | | 32,862 | | 34,878 |
繰延税金資産 | | | 1,766 | | 1,709 |
その他の非流動資産 | | | 2,817 | | 2,804 |
非流動資産合計 | | | 99,119 | | 105,854 |
資産合計 | | | 263,404 | | 265,828 |
| | | | | |
| | | | | (単位:百万円) |
| | | 前連結会計年度末 (2024年3月31日) | | 当第1四半期連結会計期間 (2024年6月30日) |
負債及び資本 | | | | | |
負債 | | | | | |
流動負債 | | | | | |
営業債務及びその他の債務 | | | 24,706 | | 21,649 |
その他の金融負債 | | | 372 | | 269 |
リース負債 | | | 1,720 | | 1,385 |
未払法人所得税 | | | 3,594 | | 896 |
その他の流動負債 | | | 6,941 | | 8,626 |
流動負債合計 | | | 37,336 | | 32,826 |
非流動負債 | | | | | |
その他の金融負債 | | | 232 | | 248 |
リース負債 | | | 1,152 | | 1,238 |
退職給付に係る負債 | | | 4,090 | | 3,993 |
その他の非流動負債 | | | 58 | | 58 |
非流動負債合計 | | | 5,533 | | 5,539 |
負債合計 | | | 42,870 | | 38,365 |
資本 | | | | | |
資本金 | | | 5,174 | | 5,174 |
資本剰余金 | | | 4,445 | | 4,445 |
利益剰余金 | | | 198,260 | | 204,348 |
自己株式 | | | △2,480 | | △2,481 |
その他の資本の構成要素 | | | 14,825 | | 15,659 |
親会社の所有者に帰属する持分合計 | | | 220,224 | | 227,147 |
非支配持分 | | | 310 | | 315 |
資本合計 | | | 220,534 | | 227,462 |
負債及び資本合計 | | | 263,404 | | 265,828 |
E0093145160日本新薬株式会社Nippon Shinyaku Co.,Ltd.四半期第3号参考様式 [IFRS](連結)IFRStrueCTE2024-04-012024-06-30Q12025-03-312023-04-012023-06-302024-03-311falsefalsefalse451602023-03-31451602024-03-31451602023-04-012023-06-30451602023-06-30451602024-04-012024-06-30451602024-06-30451602024-08-07451602023-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602023-03-31jpigp_cor:ShareCapitalIFRSMember451602023-03-31jpigp_cor:CapitalSurplusIFRSMember451602023-03-31jpigp_cor:RetainedEarningsIFRSMember451602023-03-31jpigp_cor:TreasurySharesIFRSMember451602023-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602023-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602023-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602023-03-31jpigp_cor:NonControllingInterestsIFRSMember451602024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-03-31jpigp_cor:ShareCapitalIFRSMember451602024-03-31jpigp_cor:CapitalSurplusIFRSMember451602024-03-31jpigp_cor:RetainedEarningsIFRSMember451602024-03-31jpigp_cor:TreasurySharesIFRSMember451602024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-03-31jpigp_cor:NonControllingInterestsIFRSMember451602023-04-012023-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602023-04-012023-06-30jpigp_cor:ShareCapitalIFRSMember451602023-04-012023-06-30jpigp_cor:CapitalSurplusIFRSMember451602023-04-012023-06-30jpigp_cor:RetainedEarningsIFRSMember451602023-04-012023-06-30jpigp_cor:TreasurySharesIFRSMember451602023-04-012023-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602023-04-012023-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602023-04-012023-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602023-04-012023-06-30jpigp_cor:NonControllingInterestsIFRSMember451602023-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602023-06-30jpigp_cor:ShareCapitalIFRSMember451602023-06-30jpigp_cor:CapitalSurplusIFRSMember451602023-06-30jpigp_cor:RetainedEarningsIFRSMember451602023-06-30jpigp_cor:TreasurySharesIFRSMember451602023-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602023-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602023-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602023-06-30jpigp_cor:NonControllingInterestsIFRSMember451602024-04-012024-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-04-012024-06-30jpigp_cor:ShareCapitalIFRSMember451602024-04-012024-06-30jpigp_cor:CapitalSurplusIFRSMember451602024-04-012024-06-30jpigp_cor:RetainedEarningsIFRSMember451602024-04-012024-06-30jpigp_cor:TreasurySharesIFRSMember451602024-04-012024-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-04-012024-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-04-012024-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-04-012024-06-30jpigp_cor:NonControllingInterestsIFRSMember451602024-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-06-30jpigp_cor:ShareCapitalIFRSMember451602024-06-30jpigp_cor:CapitalSurplusIFRSMember451602024-06-30jpigp_cor:RetainedEarningsIFRSMember451602024-06-30jpigp_cor:TreasurySharesIFRSMember451602024-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-06-30jpigp_cor:NonControllingInterestsIFRSMember451602023-04-012023-06-30jpcrp_cor:ReportableSegmentsMember451602023-04-012023-06-30tse-qcediffr-45160:MedicineReportableSegmentMember451602023-04-012023-06-30tse-qcediffr-45160:FunctionalFoodsReportableSegmentMember451602023-04-012023-06-30jpcrp_cor:ReconcilingItemsMember451602024-04-012024-06-30jpcrp_cor:ReportableSegmentsMember451602024-04-012024-06-30tse-qcediffr-45160:MedicineReportableSegmentMember451602024-04-012024-06-30tse-qcediffr-45160:FunctionalFoodsReportableSegmentMember451602024-04-012024-06-30jpcrp_cor:ReconcilingItemsMemberiso4217:JPYxbrli:sharesiso4217:JPYxbrli:pure